Navigation Links
Inspire Announces Positive Results of Phase 2 Trial of Epinastine,Nasal Spray for Seasonal Allergic Rhinitis

DURHAM, N.C.--(BUSINESS WIRE)--May 8, 2007 - Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) today announced results of a Phase 2 dose-ranging clinical trial comparing epinastine nasal spray and placebo in patients with seasonal allergic rhinitis. For the primary endpoint of improvement in total nasal symptom score, dose-related effects were observed in the trial, with the higher dose (0.1%) achieving statistical superiority over placebo.

Christy L. Shaffer, Ph.D., Inspire's President and CEO, stated, "We were pleased that this trial identified an effective dose of epinastine in a nasal spray formulation, demonstrated evidence of acceptable tolerability and reported a low incidence of taste complaints with the two doses evaluated. We believe the taste profile is an important and potentially differentiating attribute for a nasal antihistamine spray."

The Phase 2 clinical trial was a 14-day, randomized, double-blind comparison of two doses of epinastine nasal spray (0.05% and 0.1%) to placebo in 569 subjects who had a documented history of seasonal allergic rhinitis to mountain cedar pollen. Of the subjects randomized in the trial, 95% completed the trial and no serious adverse events were reported. While the most common adverse event observed was bitter taste, it was only reported by 4% of subjects in the 0.05% group and by 5% of subjects in the 0.1% group.

The primary endpoint of the trial was the daily reflective change from baseline for total nasal symptom score (TNSS), averaged over the 14-day treatment period. The endpoint of TNSS conforms to the U.S. Food and Drug Administration's (FDA) draft guidance document for seasonal allergic rhinitis and includes runny nose, nasal congestion, itchy nose and sneezing. Results of the trial demonstrated statistically significant improvement (p less than or equal to 0.05) in reflective TNSS for the 0.1% dose group, compared to placebo. Changes in TNSS for the 0.05% dose group were not statistically significant.

There were multiple secondary endpoints in this trial. Among these, statistically significant improvements (p less than or equal to 0.05) compared to placebo were demonstrated in the 0.1% dose group for the secondary endpoints of non-nasal symptom score (itchy eyes, watery eyes, and itchy throat/palate) and for total symptom score (TNSS plus non-nasal symptom score).

Based on the results of this trial and previous discussions with the FDA, Inspire intends to initiate a required 6-month nasal toxicology study of epinastine in a single animal species to support longer-term clinical trials. In addition, a meeting with the FDA will be scheduled to discuss the next steps in the clinical program.

In 2006, Inspire acquired certain exclusive rights from Boehringer Ingelheim International GmbH to develop and market epinastine nasal spray in the United States and Canada for the treatment or prevention of rhinitis.

About Inspire

Inspire is a biopharmaceutical company dedicated to discovering, developing and commercializing prescription pharmaceutical products in disease areas with significant commercial potential and unmet medical needs. Inspire employs a U.S. sales force for the promotion of AzaSite (azithromycin ophthalmic solution) 1% for bacterial conjunctivitis, Elestat(R) (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis(R) (cyclosporine ophthalmic emulsion) 0.05% for dry eye. Inspire is focused on the therapeutic areas of ophthalmology and respiratory/allergy, and is developing products for dry eye, cystic fibrosis, allergic rhinitis and glaucoma. Elestat and Restasis are trademarks owned by Allergan, Inc. AzaSite is a trademark owned by InSite Vision Incorporated. For more information, visit www.inspirepharm.com.

Forward-Looking Statements

The forward-looking statements in this news release relating to management's expectations and be liefs are based on preliminary information and management assumptions. Specifically, no assurances can be made with respect to: the initiation, timing and results of a 6-month nasal toxicology study; the importance and potential differentiating quality of the product candidate's taste profile; and the timing or outcome of the Company's meetings with the FDA regarding the epinastine nasal spray clinical program. Such forward-looking statements are subject to a wide range of risks and uncertainties that could cause results to differ in material respects, including those relating to additional clinical trials or discussions with the FDA regarding the epinastine nasal spray program, the amount of net sales of Restasis recorded by Allergan in 2007, the Company's 2007 financial results, including without limitation aggregate revenue, aggregate expenses, research and development expenses, selling and marketing expenses, general and administrative expenses, as well as the impact of the anticipated AzaSite launch, including without limitation headcount changes, related stock-based compensation expense changes, a draw on the Company's existing debt facility, the timing of any revised guidance, the timing and success of any additional capital raising activities, product development, revenue, expense and earnings expectations, the seasonality of Elestat, intellectual property rights, adverse litigation developments, adverse developments in the U.S. Securities and Exchange Commission (SEC) investigation, competitive products, results and timing of clinical trials, success of marketing efforts, the need for additional research and testing, delays in manufacturing, funding, and the timing and content of decisions made by regulatory authorities, including the U.S. Food and Drug Administration. Further information regarding factors that could affect Inspire's results is included in Inspire's filings with the SEC. Inspire undertakes no obligation to publicly release the results of an y revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof.

Contact

Investor Contact:
Inspire Pharmaceuticals, Inc.
Jenny Kobin, 919-941-9777, ext. 219
VP, Investor Relations and Corporate Communications
or
Media Contact:
BMC Communications
Dan Budwick, 212-477-9007, ext. 14


'"/>




Related medicine technology :

1. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. Inspire Announces Presentations at Two European Scientific Conferences
3. Inspire Announces Presentations at 2007 Association for Research in Vision and Ophthalmology Annual Meeting
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2020)... ... August 27, 2020 , ... InfoMC, a leading provider ... of their 2020 System and Organizational Controls (SOC) 1® Type 2 and SOC ... compliance assessment. These achievements reflect their long-standing commitment to privacy, security, and risk ...
(Date:8/27/2020)... , ... August 27, 2020 , ... Bleep LLC, maker ... and sleep apnea patient, is the company’s new spokesperson. , “In my line of ... So, when I found the Bleep DreamPort it was a Bleeping no brainer for ...
(Date:8/27/2020)... ... August 27, 2020 , ... The GHT Companies ... its fundraising initiative for Feeding San Diego with a press conference at ... Companies presents the final check of $5,000.00+ representing an overall donation result exceeding $30,000 ...
Breaking Medicine Technology:
(Date:9/1/2020)... ... 01, 2020 , ... Dr. Kiran Gill is a Board ... the face, breast, and body. In 2018, she founded Aesthetics in Plastic Surgery ... aesthetic practice in Southwest Florida. Dr. Gill and her team offer surgical and ...
(Date:8/31/2020)... ... ... out your dear friend has cancer? , It’s hard to hear your doctor say the ... Once the shock wears off, the questions and fears can be overwhelming. , How should ... help? Words are failing me. I’m scared. I want to DO something. , We’ve talked ...
(Date:8/31/2020)... ... August 31, 2020 , ... ... solution for chiropractors, announced today the launch of its integrated, HIPAA compliant, telehealth ... running their virtual practice in under 90 seconds. , According to the ...
(Date:8/31/2020)... ... August 31, 2020 , ... The pandemic and topsy-turvy economic outlook continues to put financial strain ... for ways to trim the fat from our monthly expenses and put more into savings, ... important that you have a financial safety net in place in case something were to ...
(Date:8/31/2020)... Calif. (PRWEB) , ... August 31, 2020 , ... ... leadership experience working, both directly with persons with autism and other developmental disabilities, ... expertise includes early intervention, parent education, adolescents with autism, school consultation, and staff ...
Breaking Medicine News(10 mins):